Talphera Inc. reported its financial results for the first quarter of 2025, highlighting a net loss from continuing operations of $2.7 million, which is an improvement from the $4.0 million net loss recorded in the same period in 2024. The reduction in net loss is primarily attributed to decreased personnel expenses and a change in the fair value of the company's warrant liability. Net loss attributable to common shareholders was reported at $2.6 million for the first quarter of 2025, down from $4.0 million in the first quarter of the previous year. The company also reported a net income from discontinued operations of $0.1 million in the first quarter of 2025. Talphera's cash and cash equivalents balance stood at $5.4 million as of March 31, 2025, with an adjusted cash position of $9.8 million after accounting for the proceeds from the first tranche of private placement financing closed on April 2, 2025. In terms of business operations, Talphera activated three new clinical study sites and began screening patients in 2025, with expectations to add five more sites by mid-year, bringing the total to 13. The company also provided guidance for 2025, projecting cash operating expenses within the range of $17 million to $19 million. Additionally, Talphera announced a financing agreement in March 2025 for up to $14.8 million, with the first tranche of $4.4 million in net proceeds closed on April 2, 2025.